Not exact matches
In healthy individuals, these
immune checkpoints prevent autoimmunity, but many cancers
exploit the same pathways to shield themselves from an
immune attack.
Microbes that cause diseases like HIV, malaria, and hepatitis C
exploit and often activate the same
checkpoint pathways — cell surface receptors such as CTLA4 and PD - 1 — to slow
immune cells and prevent their elimination by the host.
In an effort to further
exploit the potential of Pexa - Vec to activate the
immune system to fight cancer, as seen in McDonald's preclinical data, SillaJen recently announced a new clinical trial in collaboration with New York - based Regeneron Inc. to test Pexa - Vec and REGN2810, a PD - 1
checkpoint inhibitor, in combination against renal cell carcinoma, and recently signed a sponsored research agreement with UCSF to enable joint support of parallel preclinical experiments by McDonald's team.